HT
IOVA icon

Headlands Technologies’s Iovance Biotherapeutics IOVA Stock Holding History

Headlands Technologies’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$537K Buy
153,072
+82,410
+117% +$264K 0.06% 344
2025
Q4 		$193K Buy
+70,662
New +$163K 0.02% 599
2025
Q1 		– Sell
-25,725
Closed -$190K – 1331
2024
Q4 		$190K Buy
+25,725
New +$238K 0.02% 535
2024
Q3 		– Sell
-16,067
Closed -$129K – 1358
2024
Q2 		$129K Buy
+16,067
New +$172K 0.01% 574

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Headlands Technologies's IOVA Position: Q1 2026 in Review

Headlands Technologies increased its Iovance Biotherapeutics (IOVA) stake by 117% in Q1 2026, buying an estimated $264K and bringing the position to 153,072 shares worth $537K. The position accounts for 0.06% of the portfolio, ranked #344.

Headlands Technologies first reported a position in IOVA in Q2 2024 and has held it in 4 quarters since. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Headlands Technologies held 153,072 shares of Iovance Biotherapeutics worth $537K as of Q1 2026.
  • Headlands Technologies bought 82,410 Iovance Biotherapeutics shares in Q1 2026, an estimated $264K.
  • Iovance Biotherapeutics made up 0.06% of Headlands Technologies's portfolio in Q1 2026, its #344 holding.
  • Headlands Technologies first reported a position in Iovance Biotherapeutics in Q2 2024 and has held it in 4 quarters since.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.